Tryp Therapeutics, Inc. and Exopharm have successfully completed a plan of arrangement, where Exopharm acquired Tryp in an all-stock transaction. Each Tryp shareholder will receive 3.616 Exopharm Shares for each Tryp Share held. The arrangement was approved by shareholders and the Supreme Court of British Columbia. Shareholders must return necessary documents for the transaction. Tryp Shares will be de-listed, while Exopharm Shares will start trading on the Australian Securities Exchange under 'Tryptamine Therapeutics ' and the ticker symbol 'TYP'.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.